ERBB2 and breast cancer: Examples include therapies against HER2 overexpressed breast cancers (such as Trastuzumab and Lapatinib), c-Kit-targeted therapy in BCR-ABL defective leukemias (Gleevec), and VEGF/VEGF-R-targeted compounds for inhibiting cancerous angiogenesis (such as Bevacizumab).